PΔN

Details of the party (listed entity /subsidiary)

entering into the transaction

Name

1 Lupin Limited

2 Lupin Limited

3 Lupin Limited

4 Lupin Limited

5 Lupin Limited

6 Lupin Limited

7 Lupin Limited

8 Lupin Limited

9 Lupin Limited

10 Lupin Limited

11 Lupin Limited

12 Lupin Limited

13 Lupin Limited

14 Lupin Limited

15 Lupin Limited

16 Lupin Limited

17 Lupin Limited

18 Lupin Limited

19 Lupin Limited

20 Lupin Limited

21 Lupin Limited

22 Lupin Limited

23 Lupin Limited

24 Lupin Limited

25 Lupin Limited

26 Lupin Limited

27 Lupin Limited

28 Lupin Limited

29 Lupin Limited

30 Lupin Limited

31 Lupin Limited

32 Lupin Limited

33 Lupin Limited

34 Lupin Limited

35 Lupin Limited

36 Lupin Limited

37 Lupin Limited

38 Lupin Limited

39 Lupin Limited

40 Lupin Limited

41 Lupin Limited

42 Lupin Limited

43 Lupin Limited

44 Lupin Limited

45 Lupin Limited

46 Lupin Limited

47 Lupin Limited

48 Lupin Limited

49 Lupin Limited

50 Lupin Limited

51 Lupin Limited

52 Lupin Limited

53 Lupin Limited

Lupin Pharmaceuticals Inc. USA

Lupin Australia Pty Limited, Australia

Hormosan Pharma GmbH, Germany

Multicare Pharmaceuticals Philippines Inc

Lupin Atlantis Holdings SA, Switzerland

Generic Health Pty Limited, Australia

Lupin Pharma Canada Limited Canada

Lupin Diagnostics Limited, India (formerly

uthern Cross Pharma Pty Limited Australia

known as Lupin Healthcare Limited)

Lupin Digital Health Limited, India

Lupin Pharmaceuticals Inc. USA

Hormosan Pharma GmbH, Germany

Multicare Pharmaceuticals Philippines Inc.

Lupin Atlantis Holdings SA, Switzerland

Generic Health Pty Limited, Australia

Lupin Pharma Canada Limited Canada

Lupin Philippines Inc. Philippines

Pharma Dynamics (Proprietary) Limited, South

Medguimica Industria Farmaceutica LTDA Braz

Lupin Healthcare (UK) Limited, UK

Lupin Philippines Inc. Philippines

Nanomi B.V., Netherlands

Lupin Research Inc. USA

Novel Laboratories Inc. USA

Lupin Management Inc., USA

Lupin Oncology Inc., USA

Lupin Inc., USA

Philippines

Lupin Inc., USA

Lupin Research Inc. USA

Zyma Properties Pvt. Limited

Novel Laboratories Inc. USA

upin Pharmaceuticals Inc. USA

Hormosan Pharma GmbH, Germany

upin Healthcare (UK) Limited, UK

Multicare Pharmaceuticals Philippines Inc.

upin Atlantis Holdings SA, Switzerland

Generic Health Pty Limited, Australia

upin Pharma Canada Limited Canada

aboratorios Grin S.A. de C.V., Mexico

Medquimica Industria Farmaceutica LTDA Brazi

upin Philippines Inc. Philippines

Nanomi B.V., Netherlands

upin Research Inc. USA

lovel Laboratories Inc. USA

upin Management Inc., USA

Lupin Diagnostics Limited, India (formerly

known as Lupin Healthcare Limited)

upin Digital Health Limited, India

upin Inc., USA

Pharma Dynamics (Proprietary) Limited, South

Lupin Research Inc. USA

Philippines

Africa

Pharma Dynamics (Proprietary) Limited, South

Lupin Healthcare (UK) Limited, UK

Lupin Europe GmbH, Germany

Philippines

Name

Details of Related Parties transactions during the period April 1, 2022 to September 30, 2022

Details of the counterparty	

 $P\Delta N$

Relationship of the

counterparty with the listed

entity or its subsidiary

Wholly -Owned Subsidiary

Relative of KMP and Entity in which the KMP and Relatives of KMP have control or

significant influence

Wholly -Owned Subsidiary

ubsidiary

Subsidiary

Subsidiary

Subsidiary

Type of related party transaction

Sale of goods or services

Purchase of goods or services

Purchase of goods or services

Expenses incurred on their behal

Expenses incurred on their behal-

Expenses incurred on their behal

Expenses incurred on their behal

Expenses incurred on their behal-

Expenses incurred on their behal-

Expenses incurred on their behal-

Expenses incurred on their behal

Expenses incurred on their behalt

Expenses incurred on their behal-

Expenses incurred on their behal-

Expenses incurred on their behalf

Expenses incurred on their behal

Expenses incurred on their behal-

Expenses incurred on their behalf

Rent Paid

recovered

Value of the related party

transaction as approved by

the audit committee

17.79

0.22

2.49

2.45

0.35

1.67

7.16

1.50

2.34

1.82

0.47

1 96

2.12

1.99

3.99

6.2

1.66

0.03

0.18

0.5

9469.79

71.03

445.0

109.13

295.58

670.16

521.08

336.52

46.1

304.06

1685.04

59.30

14.5

323.40

67.66

10.81

6.43

5.06

7.83

4.31

13.75

4.7

2.28

0.00

7.73

9.74

1.90

26.67

10.01

5.41

23.08

2.59

reporting period when such transaction was undertaken. In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits. advances or investments

indebtedness

debtedness (loan/ Details of other

issuance of debt/

any other etc.)

n case monies are due to

ither party as a result of

Closing

balance

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

n nr

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.0

0.0

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

the transaction

Opening

balance

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

Value of transaction

during the reporting

period

17.79

0.22

2.49

2.45

0.35

1.67

7.16

1.50

2.34

1.82

0.47

1 96

2.12

1.99

3.99

6.2

1.66

0.03

0.18

0.53

9469.79

71.03

445.02

109.13

295.58

670.16

521.08

336.52

46.19

304.06

1685.04

59.30

14.55

323.40

67.66

10.81

6.43

5.06

7.83

4.3

13.75

4.71

2.28

0.00

7.73

9.74

1.90

26.67

10.01

6.70

5.43

23.08

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the

Nature (loan/ advance/

intercorporate deposit/

investment)

Cost Tenure

Rs. in Million

Purpose for which the

funds will be utilised by the

ultimate recipient of funds

(endusage)

Details of the loans, inter-corporate deposits, advances or investments

Tenure

nterest

Rate (%)

Secured/

unsecured

Rs. in Million

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

			rty			Value of transaction	either party	ies are due to as a result of	f make or give loa	ial indebtedness is ns, inter-corporati ces or investments	incurred e deposits	to	period when such transaction was undertaken. Details of the loans, inter-corporate deposits, advances or investments					
Sr No. Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	transaction as approved by the audit committee	during the reporting period	Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Details of other indebtedness	Cost Te		Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
				Relative of KMP and Entity in which the KMP and Relatives of KMP have control or														
54 Lupin Limited		Polynova Industries Limited		significant influence Relative of KMP and Entity in	Rent received	0.91	0.91	0.00	0.00	0								
55 Lupin Limited		Polynova Industries Limited		which the KMP and Relatives of KMP have control or significant influence	Inter-corporate deposit	0.00	0.00	0.10	0.10	0								
56 Lupin Limited		Mr. Nilesh D. Gupta		Key Management Personnel	Remuneration	26.53	26.53	0.00	0.00	0								
57 Lupin Management Inc., USA		Ms. Vinita Gupta		Key Management Personnel	Remuneration	52.66	52.66	0.00	0.00	0								
58 Lupin Limited		Mr. Ramesh Swaminathan		Key Management Personnel	Remuneration	34.02	9 34.02	0.00	0.00	0								
59 Lupin Limited		Mr. R. V. Satam		Key Management Personnel	Remuneration	5.29	5.29	0.00	0.00	n								
60 Lupin Limited		Dr. Kamal K. Sharma		Non- Executive Director	Sitting Fees	0.16												
61 Lupin Limited		Mr. Jean-Luc Belingard		Independent Director	Sitting Fees	0.02	0.02	0.00	0.00	0								
62 Lupin Limited		Ms. Christine Ann Mundkur	_	Independent Director	Sitting Fees	0.14							[
63 Lupin Limited		Mr. K.B.S. Anand	-	Independent Director	Sitting Fees	0.08					\vdash	\perp	\dashv					
64 Lupin Limited 65 Lupin Limited		Dr. Punita Kumar-Sinha	+	Independent Director Non- Executive Director	Sitting Fees	0.12						+	\dashv					
66 Lupin Limited		Mrs. Manju D. Gupta Mr. Mark D. Mcdade	+	Independent Director	Sitting Fees	0.08						_	_					
67 Lupin Limited		Lupin Research Inc. USA	+	Wholly -Owned Subsidiary	Sitting Fees Purchase of goods or services	168.76							\rightarrow					
or Edgin Emilied		commercial control con		Relative of KMP and Entity in which the KMP and Relatives of KMP have control or	The control of goods of scrinces	100.70	13070	0.00	0.00									
68 Lupin Limited		Shuban Prints		significant influence	Purchase of goods or services	33.15												
69 Lupin Limited		S. N. Pharma	_	Relative of KMP and Entity in	Purchase of goods or services	40.50												
70 Lupin Limited		Lupin Biologics Limited, India	_	Wholly -Owned Subsidiary	Investment	0.50							_					
71 Lupin Limited		Lupin Digital Health Limited, India	+	Wholly -Owned Subsidiary	Investment	297.00	297.00	400.10	697.10	0		_	\dashv					
72 Lupin Limited		Lupin Human Welfare and Research Foundation	1	Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence Relative of KMP and Entity in	Donation	8.79	8.79	0.00	0.00	D								
				which the KMP and Relatives of KMP have control or														
73 Lupin Limited		Mata Shree Gomati Devi Jan Seva Nidhi Lupin Pharmaceuticals Inc. USA	-	significant influence	Donation Durantees of search as a services	5.40 36.19						_						
74 Lupin Limited 75 Lupin Limited		Hormosan Pharma GmbH, Germany	+	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Purchase of goods or services	36.19 10.48						-	-					
76 Lupin Limited		Lupin Healthcare (UK) Limited, UK	+	Wholly -Owned Subsidiary	Purchase of goods or services Purchase of goods or services	75.79							-					
77 Lupin Limited		Lupin Atlantis Holdings SA, Switzerland	T	Wholly -Owned Subsidiary	Purchase of goods or services	28.99		0.00										
78 Lupin Limited		Lupin Inc., USA		Wholly -Owned Subsidiary	Purchase of goods or services	74.99												
79 Lupin Limited		Lupin Management Inc., USA		Wholly -Owned Subsidiary Relative of KMP and Entity in which the KMP and Relatives of KMP have control or	Purchase of goods or services	201.07	201.07	0.00	0.00	0								
80 Lupin Limited		Team Lease Services Limited		significant influence Relative of KMP and Entity in	Purchase of goods or services	21.79	21.79	0.00	0.00	0								
81 Lupin Limited		S. N. Pharma		which the KMP and Relatives of KMP have control or significant influence	Purchase of goods or services	13.39	13.39	0.00	0.00	0								
82 Lupin Limited		Lupin Pharmaceuticals Inc. USA		Wholly -Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	240.49	240.49	0.00	0.00	0								
					Expenses incurred on our behalf reimbursed & Other													
83 Lupin Limited	+	Lupin Australia Pty Limited, Australia	\vdash	Wholly -Owned Subsidiary	Reimbursements Expenses incurred on our behalf	29.94	29.94	0.00	0.00	0		_	+					
84 Lupin Limited		Hormosan Pharma GmbH, Germany		Wholly -Owned Subsidiary	reimbursed & Other Reimbursements	7.94	7.94	0.00	0.00									
84 Eupin Ellinteu		romosan Fhama Gilbri, Germany		Wilony -Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other	7.54	7.54	0.00	0.00									
85 Lupin Limited		Lupin Europe GmbH, Germany		Wholly -Owned Subsidiary	Reimbursements Expenses incurred on our behalf	2.31	2.31	0.00	0.00	0		_	\dashv					
86 Lupin Limited		Pharma Dynamics (Proprietary) Limited, South Africa		Wholly -Owned Subsidiary	reimbursed & Other Reimbursements	3.25	3.25	0.00	0.00	0								
				, , , , , , , , , , , , , , , , , , , ,	Expenses incurred on our behalf reimbursed & Other													
87 Lupin Limited		Generic Health Pty Limited, Australia		Wholly -Owned Subsidiary	Reimbursements Expenses incurred on our behalf	3.31	3.31	0.00	0.00	0		+	\dashv					
88 Lupin Limited		Lupin Pharma Canada Limited Canada		Wholly -Owned Subsidiary	reimbursed & Other Reimbursements	26.36	26.36	0.00	0.00	0								

0.00

0.00

0.00

0.00

21.60

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

3.39

35.86

33.19

20.22

0.00

0.00

21.60

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

35.86

3.39

33.19

6.99

20.22

0.00

32805.56

50885.21

1127.85

0.00

717 09

31.95

47 93

2.57

40.70

0.61

30.07

14.04

291.42

8.97

0.00

96.45

0.00

0.02

1.32

35.47

0.00

0.00

0.00

0.00

0.00

32805.56

50885.23

1081.6

1127.85

0.00

162 84

18.47

95.91

2.31

3.31

3.58

14.79

48.77

15.07

766.19

102.27

178.30

0.40

1.23

0.90

0.02

2.5

50.98

0.00

0.00

0.00

0.00

0.00

8.31

Wholly -Owned Subsidiary

Wholly -Owned Subsidiary

Wholly -Owned Subsidiary

Relative of KMP and Entity in which the KMP and Relatives of KMP have control or

Relative of KMP and Entity in which the KMP and Relatives of KMP have control or

significant influence

significant influence

Wholly -Owned Subsidiary

Relative of KMP and Entity in which the KMP and Relatives of KMP have control or

Relative of KMP and Entity in which the KMP and Relatives of KMP have control or

Relative of KMP and Entity in which the KMP and Relatives of KMP have control or

significant influence

significant influence

significant influence

Wholly -Owned Subsidiary

Non- Executive Director

Wholly -Owned Subsidiary

Subsidiary

Investment

Investment

Investment

Inter-corporate deposit

Inter-corporate deposit

Payables

Payables

Payables

Payables

Payables

Payables

Pavables

Payables

Pavables

Payables

Payables

Payables

Pavables

Pavables

Payables

Payables

Pavables

Payables

Pavables

Sale of fixed assets

Sale of fixed assets

ees received against guarantee

Fees received against guarantee

Fees received against guarantee

provided on their behalf

provided on their behalf

provided on their behalf

Lupin Atlantis Holdings SA, Switzerland

known as Lupin Healthcare Limited)

Lupin Diagnostics Limited, India (formerly

Nanomi B.V., Netherlands

Lupin Oncology Inc., USA

Zyma Properties Pvt. Limited

Zyma Properties Pvt. Limited

Lupin Pharmaceuticals Inc. USA

Hormosan Pharma GmbH, Germany

Lupin Atlantis Holdings SA, Switzerland

Generic Health Ptv Limited, Australia

Lupin Research Inc. USA

Novel Laboratories Inc. USA

Lupin Management Inc., USA

Team Lease Services Limited

Lupin Australia Pty Limited, Australia

Novel Laboratories Inc. USA

Nanomi B.V., Netherlands

upin Pharmaceuticals Inc. USA

Medquimica Industria Farmaceutica LTDA Brazil

Shuban Prints

S. N. Pharma

Lupin Inc., USA

Dr. Kamal K. Sharma

Lupin Digital Health Limited, India

Lupin Pharma Canada Limited Canada

Pharma Dynamics (Proprietary) Limited, South

Medquimica Industria Farmaceutica LTDA Brazi

Lupin Diagnostics Limited, India (formerly

known as Lupin Healthcare Limited)

Lupin Healthcare (UK) Limited, UK

Lupin Europe GmbH, Germany

117 Lupin Limited

97 Lupin Limited

98 Lupin Limited

99 Lupin Limited

100 Lupin Limited

101 Lupin Limited

102 Lupin Limited

103 Lupin Limited

104 Lupin Limited

105 Lupin Limited

106 Lupin Limited

107 Lupin Limited

108 Lupin Limited

109 Lupin Limited

110 Lupin Limited

111 Lupin Limited

112 Lupin Limited

113 Lupin Limited

114 Lupin Limited

115 Lupin Limited

116 Lupin Limited

118 Lupin Limited

119 Lupin Limited

120 Lupin Limited

121 Lupin Limited

122 Lupin Limited

123 Lupin Limited

124 Lupin Limited

125 Lupin Limited

126 Lupin Limited

Rs. in Million

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the

												ueposits, advances	or investments i			y the listed entity/subsidia eriod when such transactio				osed only once, during the		
	Details of the party (listed entity /subsidia entering into the transaction	ary)	Details of the count	nterp	party				eithe		s are due to s a result of	In case any financia make or give loan		s incurr te depo	ed to	to						
Sr No.		PAN	Name	PA	Relationship of the counterparty with the listed	Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	n		Closing balance	Nature of	Details of other indebtedness		Tenure		Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds		
					entity or its subsidiary				L			any other etc.)				investment)		<u> </u>		(endusage)		
	7 Lupin Limited		Lupin Atlantis Holdings SA, Switzerland		Wholly -Owned Subsidiary	Sale of goods or services	72.47		_	0.00	0.00											
	B Lupin Limited Upin Limited		Lupin Inc., USA Lupin Research Inc. USA	╁	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Sale of goods or services Sale of goods or services	8.52 0.17		-	0.00	0.00			\vdash								
	Lupin Limited		Lupin Oncology Inc., USA	t	Subsidiary	Sale of goods or services	908.89		,	0.00	0.00			\Box								
	Lupin Limited		Novel Laboratories Inc. USA		Wholly -Owned Subsidiary	Purchase of fixed assets	49.55	49.55		0.00	0.00											
422			Lupin Diagnostics Limited, India (formerly		While o colonia	B				0.00	0.00											
132	2 Lupin Limited		known as Lupin Healthcare Limited)	╁	Wholly -Owned Subsidiary	Purchase of fixed assets	0.04	0.04		0.00	0.00			\vdash								
						Settlement of liabilities by entity																
133	3 Lupin Limited		Dr. Kamal K. Sharma	_	Non- Executive Director	on behalf of related party	3.37	3.3	'	0.00	0.00											
						Letter of Comfort issued by the Company to the bankers of																
134	Lupin Limited		Lupin Pharmaceuticals Inc. USA		Wholly -Owned Subsidiary	subsidiary companies	1974.31	1974.3:		0.00	0.00											
135	Lupin Limited		Lupin Philippines Inc. Philippines		Wholly -Owned Subsidiary	Payables	0.00			0.05	0.00											
	5 Lupin Limited		Generic Health Pty Limited, Australia	1	Wholly Owned Subsidiary	Receivables	0.00			264.41	283.37			\vdash								
	7 Lupin Limited B Lupin Limited		Hormosan Pharma GmbH, Germany Laboratorios Grin S.A. de C.V., Mexico	+	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Receivables Receivables	0.00			10.60 2.68	4.13 1.27			\vdash								
139	Lupin Limited		Lupin Europe GmbH, Germany	L	Wholly -Owned Subsidiary	Receivables	0.00	0.00)	0.16	0.18											
	Lupin Limited		Lupin Atlantis Holdings SA, Switzerland	F	Wholly -Owned Subsidiary	Receivables	0.00			245.52	413.10			ш								
	L Lupin Limited Lupin Limited		Lupin Australia Pty Limited, Australia Lupin Biologics Limited, India	+	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Receivables Receivables	0.00			0.00	0.10			\vdash								
	Lupin Limited		Lupin Digital Health Limited, India	İ	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Receivables	0.00			1.34	2.86											
	Lupin Limited		Lupin Healthcare (UK) Limited, UK	F	Wholly -Owned Subsidiary	Receivables	0.00			356.28	664.12											
145	Lunin Limited		Lupin Diagnostics Limited, India (formerly known as Lupin Healthcare Limited)		Wholly -Owned Subsidia-	Receivables	0.00	0.00	,l	5.07	4.50											
	5 Lupin Limited 5 Lupin Limited		Nanomi B.V., Netherlands	t	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Receivables Receivables	0.00			7.84	24.44			\vdash								
147	7 Lupin Limited		Lupin Inc., USA	L	Wholly -Owned Subsidiary	Receivables	0.00	0.00	6	842.46	1763.45											
	B Lupin Limited D Lupin Limited		Lupin Management Inc., USA	+	Wholly -Owned Subsidiary Subsidiary	Receivables Receivables	0.00			3.10 812.57	7.37 1794.71			\vdash								
	Lupin Limited		Lupin Oncology Inc., USA Lupin Pharma Canada Limited Canada	+	Wholly -Owned Subsidiary	Receivables	0.00			248.36	333.27			\vdash								
	Lupin Limited		Lupin Pharmaceuticals Inc. USA		Wholly -Owned Subsidiary	Receivables	0.00			801.67	13621.33											
	2 Lupin Limited		Lupin Philippines Inc. Philippines	F	Wholly -Owned Subsidiary	Receivables	0.00			270.73	238.18			\Box								
153	B Lupin Limited		Lupin Research Inc. USA	+	Wholly -Owned Subsidiary	Receivables	0.00	0.00	+	30.92	53.84			\vdash								
154	Lupin Limited		Medquimica Industria Farmaceutica LTDA Brazil Multicare Pharmaceuticals Philippines Inc.	-	Wholly -Owned Subsidiary	Receivables	0.00	0.00		374.35	275.73											
	5 Lupin Limited		Philippines		Subsidiary	Receivables	0.00			52.52	75.54			\sqcup								
156	5 Lupin Limited		Novel Laboratories Inc. USA	╀	Wholly -Owned Subsidiary	Receivables	0.00	0.00)	5.82	39.15											
157	7 Lupin Limited		Pharma Dynamics (Proprietary) Limited, South Africa		Wholly -Owned Subsidiary	Receivables	0.00	0.00	,	173.72	179.03											
				T																		
158	3 Lupin Limited		Southern Cross Pharma Pty Limited Australia	\vdash	Wholly -Owned Subsidiary	Receivables	0.00	0.00		0.00	0.35			\vdash								
						Corporate guarantees issued by the Company to the bankers of																
159	Lupin Limited		Generic Health Pty Limited, Australia	1	Wholly -Owned Subsidiary	subsidiary company	0.00	0.00)	0.00	1320.44			\sqcup								
						Corporate guarantons issued but																
						Corporate guarantees issued by the Company to the bankers of																
160	Lupin Limited		Lupin Healthcare (UK) Limited, UK	L	Wholly -Owned Subsidiary	subsidiary company	0.00	0.00		64.65	59.02			Ш								
						Corporate guarantena income to																
						Corporate guarantees issued by the Company to the bankers of																
161	Lupin Limited		Lupin Pharmaceuticals Inc. USA	L	Wholly -Owned Subsidiary	subsidiary company	0.00	0.00	28	895.89	35080.03			\sqcup								
						Corporate guarantena income to																
						Corporate guarantees issued by the Company to the bankers of																
162	2 Lupin Limited		Medquimica Industria Farmaceutica LTDA Brazil	L	Wholly -Owned Subsidiary	subsidiary company	0.00	0.00	5	840.19	2056.50											
						Guarantees issued by the					T			T						7.		
						Company on behalf of subsidiary company for contractual																
163	3 Lupin Limited		Nanomi B.V., Netherlands		Wholly -Owned Subsidiary	obligations	0.00	0.00	5	075.07	5446.86											
					Esta harrant ta						T			T	_					7.		
164	Lupin Limited		Lupin Investments Pvt. Limited		Entity having significant influence over the company	Dividend paid	828.78	828.78		0.00	0.00											
104				T		Jeno para	028.76	028.76		5.00	0.00			\Box								
					Relative of KMP and Entity in																	
					which the KMP and Relatives of KMP have control or																	
165	5 Lupin Limited		Dr. Anuja Gupta (Daughter of Chairman)	L	significant influence	Dividend paid	2.90	2.90	<u> </u>	0.00	0.00											
					Deliver of the second									ΙП								
					Relative of KMP and Entity in which the KMP and Relatives																	
					of KMP have control or																	
166	Lupin Limited		Ms. Kavita Gupta (Daughter of Chairman)	1	significant influence	Dividend paid	0.80	0.80	<u> </u>	0.00	0.00			\sqcup								
					Relative of KMP and Entity in																	
					which the KMP and Relatives																	
					of KMP have control or	[
167	7 Lupin Limited		Dr. Richa Gupta (Daughter of Chairman)	_	significant influence	Dividend paid	0.93	0.9	1	0.00	0.00			ш								

Deta	ils of Related Parties transactions during the peri	iod April 1, 2022 to September 30, 2022																Rs. in Million			
	G									Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corpor deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during reporting period when such transaction was undertaken.											
						deposits, advance	s or investments r														
	Details of the party (listed entity /subsidiary)	Details of the count	orna	rtu					nies are due to y as a result of												
	entering into the transaction	Details of the count	егра	rty					y as a result of ansaction		ans, inter-corporat ces or investment		SILS,	Details of the loans, inter-corporate deposits, advances or investments							
Sr	I	+		T	T of coloted and the constitut	Value of the related party	Value of transaction				1						1				
No.				Relationship of the	Type of related party transaction	transaction as approved by the audit committee	during the reporting period			Nature of				Nature (loan/ advance/				Purpose for which the			
	Name PAI	N Name	PAN					Opening	Closing	indebtedness (loan/		Cost	Tenure	intercorporate deposit/	Interest	Tenure	Secured/	funds will be utilised by the			
				entity or its subsidiary				balance	balance	issuance of debt/	indebtedness			investment)	Rate (%)		unsecured	ultimate recipient of funds (endusage)			
ш										any other etc.)								(endusage)			
				Relative of KMP and Entity in																	
				which the KMP and Relatives																	
		Ms. Shefali Nath Gupta (Wife of Managing		of KMP have control or																	
168	Lupin Limited	Director)		significant influence	Dividend paid	0.01	0.01	0.0	0.00	o l											
				Relative of KMP and Entity in																	
		Miss Veda Nilesh Gupta (Daughter of Managing		which the KMP and Relatives of KMP have control or																	
169	Lupin Limited	Director)		significant influence	Dividend paid	0.28	0.28	0.0	0.00												
				Relative of KMP and Entity in																	
		Marter Neel Deckhandhii Ciinte /Son of		which the KMP and Relatives of KMP have control or					1												
170	Lupin Limited	Master Neel Deshbandhu Gupta (Son of Managing Director)		of KMP have control or significant influence	Dividend paid	0.10	0.10	0.0	0.00												
1/5				B-meant imacrice		0.10	3.10	3.0	0.00			\vdash									
				Relative of KMP and Entity in					1												
				which the KMP and Relatives																	
,_,	Lupin Limited	D. B. Gupta (HUF)		of KMP have control or	Dividend no:																
	Lupin Limited Lupin Limited	D. B. Gupta (HUF) Mrs. Manju D. Gupta		significant influence Non- Executive Director	Dividend paid Dividend paid	2.59		0.0				\vdash				—					
1					para	15.40	25.40	3.0	5.00			\Box									
				Relative of KMP and Entity in																	
				which the KMP and Relatives																	
172	Lupin Limited	Mrs. Manju D. Gupta (as Trustee of Gupta Family Trust)		of KMP have control or significant influence	Dividend paid	0.00	0.00	0.0	0.00												
	Lupin Limited Lupin Limited	Dr. Kamal K. Sharma		Non- Executive Director	Dividend paid Dividend paid	0.00						\vdash									
						0.50	0.50	0.0	5.00	1		\Box									
175	Lupin Limited	Ms. Vinita Gupta		Key Management Personnel	Dividend paid	1.31	1.31	0.0	0.00	D		\sqcup									
		has artists a control			Dr. Marchaeld																
176	Lupin Limited	Mr. Nilesh D. Gupta		Key Management Personnel	Dividend paid	3.60	3.60	0.0	0.00	1		\vdash									
177	Lupin Limited	Mr. Ramesh Swaminathan		Key Management Personnel	Dividend paid	0.01	0.01	0.0	0.00	D		L l									
	Lupin Limited	Dr. Punita Kumar-Sinha		Independent Director	Dividend paid	0.00															
	Ii. Limited	Ma B V Catara		Kan Managan	Dividend anid		0.02														
	Lupin Limited Multicare Pharmaceuticals Philippines Inc.	Mr. R. V. Satam		Key Management Personnel	Dividend paid	0.02	0.02	0.0	0.00)		\vdash									
	Philippines	Lupin Philippines Inc. Philippines		Fellow Subsidiary	Sale of goods or services		0.17	0.0	0.00												
	Multicare Pharmaceuticals Philippines Inc.																				
	Philippines	Lupin Philippines Inc. Philippines		Fellow Subsidiary	Purchase of goods or services		103.70	0.0	0.00												
	Multicare Pharmaceuticals Philippines Inc. Philippines	Lupin Philippines Inc. Philippines		Fellow Subsidiary	Payables		0.00	255.1	.6 288.50												
	Multicare Pharmaceuticals Philippines Inc.						5.03														
	Philippines	Lupin Philippines Inc. Philippines		Fellow Subsidiary	Receivables		0.00	0.0													
184	Generic Health Pty Limited, Australia	Lupin Australia Pty Limited, Australia		Fellow Subsidiary	Purchase of goods or services		0.25	0.0	0.00	9	-	\vdash									
					Expenses incurred on our behalf reimbursed & Other																
185	Generic Health Pty Limited, Australia	Lupin Australia Pty Limited, Australia		Fellow Subsidiary	Reimbursements		1.96	0.0	0.00												
186	Generic Health Pty Limited, Australia	Lupin Australia Pty Limited, Australia		Fellow Subsidiary	Loan		14.06	2.8	4 16.90)											
	Generic Health Pty Limited, Australia	Lupin Australia Pty Limited, Australia		Fellow Subsidiary	Receivables		0.00					ш									
188	Generic Health Pty Limited, Australia	Lupin Australia Pty Limited, Australia		Fellow Subsidiary	Payables		0.00	0.1	.4 0.29	9	-	\vdash				-	-				
189	Generic Health Ptv Limited, Australia	Southern Cross Pharma Ptv Limited Australia		Fellow Subsidiary	Investment		0.00	1665.9	5 1665.95	<u>.</u>											
	,,	,		,								\Box									
190	Generic Health Pty Limited, Australia	Southern Cross Pharma Pty Limited Australia		Fellow Subsidiary	Loan		46.36	17.0	2 63.38	3	1	$\vdash \vdash$									
101	Generic Health Pty Limited, Australia	Southern Cross Pharma Pty Limited Australia		Fellow Subsidiary	Payables		0.00	0.0	0 14.47	,											
131	25 readarrey Ellinteu, Adstralia	222 and in Gross i manna i ty Emilieu Australia		. Show Substituting	,		0.00	0.0	14.47	1		\vdash									
192	Lupin Atlantis Holdings SA, Switzerland	Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Receivables		0.00	38.2	6 64.97	7		Ш									
	I a sub-unitaria de la compania del compania del compania de la compania del compania de la compania del compania de la compania del c			Sally Charles	Description																
193	Lupin Atlantis Holdings SA, Switzerland	Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Receivables		0.00	110.7	2 63.88	5	1	\vdash					-				
194	Lupin Atlantis Holdings SA, Switzerland	Nanomi B.V., Netherlands		Fellow Subsidiary	Receivables		0.00	1.7	6 1.55	5		L l					<u></u>				
		·																			
195	Lupin Atlantis Holdings SA, Switzerland	Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Receivables		0.00	1057.0	7 1219.53	3		$\vdash \vdash$				-					
196	Lupin Atlantis Holdings SA, Switzerland	Pharma Dynamics (Proprietary) Limited, South Africa		Fellow Subsidiary	Receivables		0.00	1.6	6 1.54	1											
123	, and the same of						5.00	2.0	1.5			\vdash									
197	Lupin Atlantis Holdings SA, Switzerland	Lupin Inc., USA		Fellow Subsidiary	Receivables		0.00	1.5	8 0.00	p		\sqcup									
100	Lupin Atlantis Holdings SA, Switzerland	Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Pavables		0.00	12.7		,											
198	Lupin Atlantis noitings 5A, SWITZERIAND	normosan Pharma GmbH, Germany		renow subsidiary	Payables		0.00	12./	3 62.01	+	1	\vdash					-				
199	Lupin Atlantis Holdings SA, Switzerland	Lupin Europe GmbH, Germany		Fellow Subsidiary	Payables		0.00	19.5	3 4.99	9											
200	Lupin Atlantis Holdings SA, Switzerland	Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Payables		0.00	5.2	5 13.08	3	-	\vdash									
201	Lupin Atlantis Holdings SA, Switzerland	Lupin Inc., USA		Fellow Subsidiary	Payables		0.00	6.5	0 3.78	3											
												\Box									
202	Lupin Atlantis Holdings SA, Switzerland	Lupin Management Inc., USA		Fellow Subsidiary	Payables		0.00	19.0	0 15.22	2	1	\sqcup					1				
202	Lupin Atlantis Holdings SA, Switzerland	Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Payables		0.00	88.1	.0 193.57	,											
203	zapin Adamas Holumgs SA, SWIZEHallu	Espirit narma Canada Ellilleu Canada		I CHOM Subsidially	j. dyddies	1	0.00	00.1	155.57	'1	1										

upin Pharmaceuticals Inc. USA

aboratorios Grin S.A. de C.V., Mexico

upin Research Inc. USA

Nanomi B.V., Netherlands

upin Europe GmbH, Germany

upin Inc., USA

upin Inc., USA

upin Healthcare (UK) Limited, UK

upin Pharma Canada Limited Canada

aboratorios Grin S.A. de C.V., Mexico

upin Healthcare (UK) Limited, UK

Nanomi B.V., Netherlands

Medguimica Industria Farmaceutica LTDA Brazi

Medquimica Industria Farmaceutica LTDA Brazi

Medquimica Industria Farmaceutica LTDA Brazil

Hormosan Pharma GmbH. Germany

unin Pharma Canada Limited Canada

upin Pharmaceuticals Inc. USA

upin Management Inc., USA

upin Pharmaceuticals Inc. USA

Hormosan Pharma GmbH, Germany

upin Healthcare (UK) Limited, UK

Hormosan Pharma GmbH, Germany

upin Healthcare (UK) Limited, UK

upin Pharmaceuticals Inc. USA

upin Europe GmbH, Germany

Hormosan Pharma GmbH, Germany

upin Research Inc. USA

Lupin Inc., USA

upin Pharma Canada Limited Canada

Pharma Dynamics (Proprietary) Limited, South

Nanomi B.V., Netherlands

upin Inc., USA

aboratorios Grin S.A. de C.V., Mexico

upin Healthcare (UK) Limited, UK

lanomi B.V., Netherlands

upin Inc., USA

upin Inc., USA

entity or its subsidiary

Payables

Payables

Payables

Investment

Investment

nvestment

Investment

Investment

Loan

Loan

Loan

nterest received

Interest received

nterest received

nterest received

Dividend received

nterest received

Sale of goods or services

Sale of goods or services

Sale of goods or services

Purchase of goods or services

Reimbursements

Reimbursements

Reimbursements

Expenses incurred on our behalf reimbursed & Other

Expenses incurred on our behalf reimbursed & Other

Expenses incurred on our behalf reimbursed & Other

Other Income

Other Income

Other Income

Other Income

Other Income

Fellow Subsidiary

entering into the transaction

Name

204 Lupin Atlantis Holdings SA, Switzerland

205 Lupin Atlantis Holdings SA, Switzerland

206 Lupin Atlantis Holdings SA, Switzerland

207 Lupin Atlantis Holdings SA, Switzerland

208 Lupin Atlantis Holdings SA, Switzerland

209 Lupin Atlantis Holdings SA, Switzerland

210 Lupin Atlantis Holdings SA, Switzerland

211 Lupin Atlantis Holdings SA, Switzerland

212 Lupin Atlantis Holdings SA, Switzerland

213 Lupin Atlantis Holdings SA, Switzerland

214 Lupin Atlantis Holdings SA, Switzerland

215 Lupin Atlantis Holdings SA, Switzerland

216 Lupin Atlantis Holdings SA, Switzerland

217 Lupin Atlantis Holdings SA, Switzerland

218 Lupin Atlantis Holdings SA, Switzerland

219 Lupin Atlantis Holdings SA, Switzerland

220 Lupin Atlantis Holdings SA, Switzerland

221 Lupin Atlantis Holdings SA, Switzerland

222 Lupin Atlantis Holdings SA, Switzerland

223 Lupin Atlantis Holdings SA, Switzerland

224 Lupin Atlantis Holdings SA, Switzerland

225 Lupin Atlantis Holdings SA, Switzerland

226 Lupin Atlantis Holdings SA, Switzerland

227 Lupin Atlantis Holdings SA, Switzerland

228 Lupin Atlantis Holdings SA, Switzerland

229 Lupin Atlantis Holdings SA, Switzerland

230 Lupin Atlantis Holdings SA, Switzerland

231 Lupin Atlantis Holdings SA, Switzerland

232 Lupin Atlantis Holdings SA, Switzerland

233 Lupin Atlantis Holdings SA, Switzerland

234 Lupin Atlantis Holdings SA, Switzerland

235 Lupin Atlantis Holdings SA, Switzerland

236 Lupin Atlantis Holdings SA, Switzerland

237 Lupin Atlantis Holdings SA, Switzerland

238 Lupin Atlantis Holdings SA, Switzerland

239 Lupin Atlantis Holdings SA, Switzerland

240 Lupin Atlantis Holdings SA, Switzerland

241 Lupin Atlantis Holdings SA, Switzerland

242 Lupin Atlantis Holdings SA, Switzerland

5.32% 9 yrs

1.25% 2 yrs

1.75% 3 yrs

2.00% 3 yrs

2.25% 3 yrs

Unsecured Business Purpose

Unsecured Business Purpose

Unsecured Business Purpose

Insecured Business Purpose

Business Purpose

Rs in Million

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

1554 56

126.04

69.26

640.67

166 56

572.69

10.54

4.80

23.91

246.92

5.56

436.35

743.21

0.00

7.68

29.28

0.82

15.26

4.57

1.49

3.03

0.00

122.20

25.53

184.5

0.81

13.77

8.18

0.12

0.00

476.16

14.91

0.00

6149.55

40 95

279.75

250.7

4170.25

21222 04

439.87

795.64

341.47

2273 79

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.84

5.66

1.87

6149.55

40 95

279.7

4170.25

22776.60

313.83

726.38

982.15

2440.35

572 69

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00 0.00

0.00

0.00

0.00

0.00

0.00

0.0

0.00

0.00

0.00

0.00

0.00

0.00

0.00

of		ns, inter-corporat es or investment		osits,	Details of the loar	ns, inter-co	orporate o	leposits, adva	ances or investments
•	Nature of indebtedness (loan/issuance of debt/	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tonuro		Purpose for which the funds will be utilised by the ultimate recipient of fund

In case any financia make or give loar advanc		e dep		Details of the loar	ns, inter-co	orporate o	deposits, adva	nces or investments
Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate

PAN

Name

243 Lupin Atlantis Holdings SA, Switzerland

244 Lupin Atlantis Holdings SA, Switzerland

245 Lupin Atlantis Holdings SA, Switzerland

246 Lupin Atlantis Holdings SA, Switzerland

247 Lupin Atlantis Holdings SA, Switzerland

248 Lupin Atlantis Holdings SA, Switzerland

249 Lupin Atlantis Holdings SA, Switzerland

250 Lupin Atlantis Holdings SA, Switzerland

251 Nanomi B.V., Netherlands

252 Nanomi B.V., Netherlands

253 Nanomi B.V., Netherlands

254 Nanomi B.V., Netherlands

255 Nanomi B.V., Netherlands

256 Nanomi B.V., Netherlands

257 Nanomi B.V., Netherlands

258 Nanomi B.V., Netherlands

259 Nanomi B.V., Netherlands

260 Nanomi B.V., Netherlands

261 Nanomi B.V., Netherlands

262 Nanomi B.V., Netherlands

263 Nanomi B.V., Netherlands

270 Lupin Inc., USA

271 Lupin Inc., USA

272 Lupin Inc., USA

273 Lupin Inc., USA

274 Lupin Inc., USA

275 Lupin Inc., USA

276 Lupin Inc., USA

277 Lupin Oncology Inc., USA

278 Lupin Oncology Inc., USA

279 Lupin Management Inc., USA

280 Lupin Management Inc., USA

281 Lupin Management Inc., USA

282 Lupin Management Inc., USA

283 Lupin Management Inc., USA

284 Lupin Management Inc., USA

285 Lupin Management Inc., USA

286 Lupin Management Inc., USA

287 Lupin Management Inc., USA

288 Lupin Management Inc., USA

289 Lupin Management Inc., USA

290 Lupin Management Inc., USA

291 Lupin Management Inc., USA

292 Lupin Management Inc., USA

293 Lupin Management Inc., USA

294 Lupin Management Inc., USA

264 Hormosan Pharma GmbH, Germany

265 Hormosan Pharma GmbH, Germany

266 Hormosan Pharma GmbH, Germany

267 Hormosan Pharma GmbH, Germany

268 Hormosan Pharma GmbH, Germany

269 Hormosan Pharma GmbH, Germany

Details of the party (listed entity /subsidiary)
entering into the transaction
Details of the counterp

upin Europe GmbH, Germany

Iormosan Pharma GmbH, Germany

upin Pharma Canada Limited Canada

upin Pharma Canada Limited Canada

upin Pharma Canada Limited Canada

Medquimica Industria Farmaceutica LTDA Brazi

Medquimica Industria Farmaceutica LTDA Brazil

Pharma Dynamics (Proprietary) Limited, South

Medquimica Industria Farmaceutica LTDA Braz

Multicare Pharmaceuticals Philippines Inc.

Multicare Pharmaceuticals Philippines Inc.

Generic Health Pty Limited, Australia

Hormosan Pharma GmbH, Germany

Hormosan Pharma GmbH, Germany

Lupin Mexico S.A. de C.V., Mexico

Generic Health SDN. BHD., Malaysia

Lupin Philippines Inc. Philippines

Lupin Europe GmbH, Germany

Lupin Europe GmbH, Germany

Lupin Europe GmbH, Germany

Lupin Europe GmbH, Germany

Nanomi B.V., Netherlands

Nanomi B.V., Netherlands

Lupin Oncology Inc., USA

upin Oncology Inc., USA

Lupin Research Inc. USA

Lupin Research Inc. USA

Lupin Management Inc., USA

Nanomi B.V., Netherlands

Lupin Oncology Inc., USA

upin Oncology Inc., USA

Lupin Inc., USA

Philippines

Lupin Pharma Canada Limited Canada

Lupin Pharma Canada Limited Canada

Lupin Pharma Canada Limited Canada

Medguimica Industria Farmaceutica LTDA Brazil

Multicare Pharmaceuticals Philippines Inc.

Laboratorios Grin S.A. de C.V., Mexico

Generic Health Pty Limited, Australia

Lupin Pharma Canada Limited Canada

Lupin Pharma Canada Limited Canada

Generic Health Ptv Limited, Australia

Generic Health Ptv Limited, Australia

Laboratorios Grin S.A. de C.V., Mexico

Laboratorios Grin S.A. de C.V., Mexico

Lupin Pharma Canada Limited Canada

upin Pharma Canada Limited Canada

Medquimica Industria Farmaceutica LTDA Brazil

upin Research Inc. USA

L Biologics Ltd., Japan

YL Biologics Ltd., Japan

Philippines

Philippines

Lupin Inc., USA

Name

|--|

Relationship of the

counterparty with the listed

entity or its subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

lointly Controlled Entity

Jointly Controlled Entity

Fellow Subsidiary

ellow Subsidiary

Fellow Subsidiary

ellow Subsidiary

Fellow Subsidiary

Valu
Type of related party transaction trans

Expenses incurred on our behalf reimbursed & Other

Reimbursements

Reimbursements

Reimbursements

Reimbursements

Reimbursements

Reimbursements

Reimbursements

Interest received

Dividend received

Investment

Investment

Investment

Investment

Investment

Investment

Investment

Investment

Investment

Receivables

Receivables

Receivables

recovered

Receivables

Payables

Payables

Receivables

Receivables

Receivables

Receivables

Receivables

Receivables

recovered

recovered

recovered

recovered

Sale of goods or services

Expenses incurred on their behalt

Expenses incurred on their behalf

Expenses incurred on their behal

Expenses incurred on their behal-

Payables

Loan

Pavables

Purchase of goods or services

Legal and Professional Expenses

Expenses incurred on their behal-

Sale of goods or services

Sale of goods or services

Interest received

Loan

Payables

Receivables

Value of the related party transaction as approved by the audit committee

Value of transaction during the reporting period

16.76

2 29

0.00

0.43

0.00

0.00

4.24

44.42

12.75

125 66

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

4.71

17.93

0.39

0.00

0.26

0.00

0.00

0.00

21 95

0.00

0.00

10.66

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

3.64

0.5

18.83

6.54

0.31

4.35

0.63

18.23

n case monies are due to

ither party as a result o

the transaction

Closing

balance

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

n nr

1188.67

1207.73

6878.78

250.56

52.15

59 89

9.29

60232.04

1316.7

126.33

0.00

0.00

0.00

0.28

7.23

14.33

0.00

n nr

0.00

0.00

14.33

2.74

10.08

9.96

9.98

2.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

909.50

0.0

650.76

Opening

balance

0.00

0.00

0.00

0.00

0.00

0.00

20.40

0.00

606.34

0.00

0.00

1188.67

1207.73

6878.78

250.56

52.15

59 89

9.29

60232.04

1316.7

126.33

0.00

0.00

0.00

0.00

0.00

0.08

1.13

0.07

0.00

158.50

909 50

0.00

1.13

0.00

24.34

13.43

3.95

10.68

0.00

0.00

0.00

0.00

0.00

0.00

0.00

In case any financial indebtedness is incurred to

make or give loans, inter-corporate deposits.

advances or investments

indebtedness

debtedness (loan/ Details of other

Nature of

issuance of debt/

any other etc.)

Rs. in Million

Purpose for which the

funds will be utilised by th

ultimate recipient of funds

(endusage)

Details of the loans, inter-corporate deposits, advances or investments

Tenure

4.00% 3 yrs

Unsecured Business Purpose

0.75% 2 yrs Unsecured Business Purpose

Secured/

nterest

Rate (%)

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Nature (loan/ advance/

intercorporate deposit/

investment)

Loan

Cost Tenure

Details of the party (listed entity /subsidiary) Details of the counterparty entering into the transaction Value of the related party Value of transaction transaction as approved by Type of related party transaction during the reporting Relationship of the the audit committee period PAN Name PAN | counterparty with the listed Name entity or its subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidian

Fellow Subsidiary

ellow Subsidiary

Fellow Subsidiary

ellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

ellow Subsidiary

Fellow Subsidiary

ellow Subsidiary

Fellow Subsidiary

Medquimica Industria Farmaceutica LTDA Brazi

Multicare Pharmaceuticals Philippines Inc.

Multicare Pharmaceuticals Philippines Inc.

Lupin Pharma Canada Limited Canada

Lupin Pharma Canada Limited Canada

Lupin Pharma Canada Limited Canada

Philippines

Philippines

Nanomi B.V., Netherlands

lanomi B.V., Netherlands

Lupin Research Inc. USA

Nanomi B.V., Netherlands

Nanomi B.V., Netherlands

Lupin Management Inc., USA

Lupin Pharmaceuticals Inc. USA

Lupin Pharmaceuticals Inc. USA

Lupin Pharmaceuticals Inc. USA

Lupin Research Inc. USA

Lupin Research Inc. USA

Lupin Research Inc. USA

Novel Laboratories Inc. USA

Novel Laboratories Inc. USA

Lupin Management Inc., USA

Lupin Pharmaceuticals Inc. USA

Lupin Pharmaceuticals Inc. USA

upin Pharmaceuticals Inc. USA

Lupin Management Inc., USA

Novel Laboratories Inc. USA

Lupin Research Inc. USA

upin Research Inc. USA

upin Management Inc., USA

Novel Laboratories Inc. USA

upin Pharmaceuticals Inc. USA

Lupin Pharmaceuticals Inc. USA

Lupin Management Inc., USA

Lupin Management Inc., USA

Lupin Management Inc., USA

Lupin Pharmaceuticals Inc. USA

upin Inc., USA

Lupin Inc., USA

Lupin Inc., USA

Lupin Inc., USA

Lupin Inc., USA

Lunin Inc., USA

upin Inc., USA

Lupin Inc., USA

Lupin Inc., USA

upin Inc., USA

Lupin Inc., USA

Lupin Inc., USA

Lupin Research Inc. USA

Lupin Management Inc., USA

Novel Laboratories Inc. USA

Lupin Research Inc. USA

Lupin Research Inc. USA

Novel Laboratories Inc. USA

Novel Laboratories Inc. USA

Lupin Management Inc., USA

upin Management Inc., USA

Lupin Pharmaceuticals Inc. USA

Lupin Pharmaceuticals Inc. USA

Lupin Research Inc. USA

Lupin Management Inc., USA

Novel Laboratories Inc. USA

Lupin Management Inc., USA

Lupin Pharmaceuticals Inc. USA

Lupin Inc., USA

Details of Related Parties transactions during the period April 1, 2022 to September 30, 2022

295 Lupin Management Inc., USA

296 Lupin Management Inc., USA

297 Lupin Management Inc., USA

298 Lupin Management Inc., USA

299 Lupin Management Inc., USA

300 Lupin Pharmaceuticals Inc. USA

301 Lupin Pharmaceuticals Inc. USA

302 Lupin Pharmaceuticals Inc. USA

303 Lupin Pharmaceuticals Inc. USA

306 Lupin Pharma Canada Limited Canada

307 Lupin Pharma Canada Limited Canada

308 Lupin Pharma Canada Limited Canada

304 Lupin Research Inc. USA

305 Lupin Research Inc. USA

309 Lupin Inc., USA

310 Lupin Inc., USA

311 Lupin Inc., USA

312 Lupin Inc., USA

313 Lupin Inc., USA

314 Lupin Inc., USA

315 Lupin Inc., USA

316 Lupin Inc., USA

317 Lupin Inc., USA

318 Lupin Inc., USA

319 Lupin Inc., USA

320 Lupin Inc., USA

321 Lupin Inc., USA

322 Lupin Inc., USA

323 Lupin Inc., USA

324 Lupin Inc., USA

325 Lupin Inc., USA

326 Lupin Inc., USA

327 Lupin Inc., USA

328 Lupin Inc., USA

329 Novel Laboratories Inc. USA

330 Novel Laboratories Inc. USA

331 Novel Laboratories Inc. USA

332 Novel Laboratories Inc. USA

333 Novel Laboratories Inc. USA

334 Novel Laboratories Inc. USA

335 Novel Laboratories Inc. USA

336 Lupin Research Inc. USA

337 Lupin Research Inc. USA

338 Lupin Research Inc. USA

339 Lupin Research Inc. USA

340 Lupin Research Inc. USA

341 Lupin Research Inc. USA

342 Lupin Pharmaceuticals Inc. USA

343 Lupin Pharmaceuticals Inc. USA

344 Lupin Pharmaceuticals Inc. USA

345 Lupin Pharmaceuticals Inc. USA

346 Lupin Pharmaceuticals Inc. USA

347 Lupin Pharmaceuticals Inc. USA

348 Lupin Pharmaceuticals Inc. USA

349 Lupin Pharmaceuticals Inc. USA

350 Lupin Pharmaceuticals Inc. USA

351 Lupin Pharmaceuticals Inc. USA

352 Lupin Pharmaceuticals Inc. USA

353 Lupin Pharmaceuticals Inc. USA

354 Lupin Pharmaceuticals Inc. USA

355 Lupin Pharmaceuticals Inc. USA

356 Lupin Pharmaceuticals Inc. USA

357 Lupin Management Inc., USA

358 Lupin Management Inc., USA

359 Lupin Management Inc., USA

Expenses incurred on their behalf

Expenses incurred on their behal-

Expenses incurred on their behal

Expenses incurred on their beha

Expenses incurred on their behal-

Sale of goods or services

recovered

recovered

recovered

recovered

Receivables

Receivables

Receivables

recovered

Payables

Payables

Investment

Receivables

Receivables

Investment

Receivables

Receivables

Payables

Payables

Payables

Payables

recovered

recovered

recovered

recovered

recovered

Receivables

recovered

Receivables

Payables

Payables

Payables

Payables

Receivables

recovered

Receivables

Receivables

Receivables

recovered

recovered

recovered

recovered

recovered

Payables

Pavables

Investment

Sale of goods or services

Sale of goods or services Expenses incurred on their behal

Expenses incurred on their behal-

Expenses incurred on their behalf

Expenses incurred on their behalf

Expenses incurred on their behalf

Expenses incurred on their behal

Sale of goods or services

Sale of goods or services

Sale of goods or services Expenses incurred on their hehal-

Sale of goods or services Expenses incurred on their hehal

Sale of goods or services

Sale of goods or services Expenses incurred on their behal

Sale of goods or services

Expenses incurred on their behalf

Expenses incurred on their behal

Expenses incurred on their beha

Opening balance 2.48

16.31

2.2

8.98

0.64

1.35

2.09

0.00

0.00

26.56

0.00

0.08

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

6532.29

70.20

31.45

36.29

35.16

13.03

20.28

18 10

14.22

30.98

0.00

24.09

2892.29

222.62

0.00

0.00

0.00

0.00

0.00

0.00

517.13

193.36

0.00

0.00

0.00

0.00

0.00

4.87

12.9

8 16

37.10

39.04

6.01

58.26

7.34

15.29

18.56

5.93

n case monies are due to

ither party as a result o

the transaction

0.00

0.00

0.00

0.00

0.00

0.00

0.00

4.70

0.97

0.00

39.86

1.07

0.96

610.42

0.00

0.00

769.10

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

1235.70

6172.57

11072.40

Closing

0.00

0.00

0.00

0.00

n nr

0.00

0.00

0.00

1.30

0.00

2.42

1.30

0.00

610.42

153.89

769.13

0.00

13.83

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.62

0.00

0.00

11.82 4.23

153.89

2.65

0.00

0.00

0.00

4 23

0.00

0.62

5.09

0.00

0.00

0.00

0.00

0.0

0.00

0.00

0.00

0.00

0.00

0.00

0.00

20809.87

1414.60

0809.87

1414.60

6172.57

27.56

In case any financial indebtedness is incurred to

make or give loans, inter-corporate deposits,

advances or investments

indebtedness

debtedness (loan/ Details of other

Nature of

issuance of debt/

any other etc.)

Rs. in Million

Purpose for which the

funds will be utilised by the

ultimate recipient of fund:

(endusage)

Details of the loans, inter-corporate deposits, advances or investments

Tenure

Secured/

nterest

Rate (%)

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Nature (loan/ advance/

investment)

Cost | Tenure | intercorporate deposit/

Deta	ails of Related Parties transactions during the	e perio	d April 1, 2022 to September 30, 2022																Rs. in Million
													ade o	r given b		ry. These d	etails ne		s to loans, inter-corporate osed only once, during the
c.	Details of the party (listed entity /subsidiary) entering into the transaction Sr					eith				ies are due to as a result of nsaction	In case any financi make or give loar advanc			Details of the loans, inter-corporate deposits, advances or investments					
No.	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	transaction as approved by the audit committee	during the reporting period	Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
200	Lupin Management Inc., USA		Lupin Research Inc. USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		0.70	0.00	0.00									
	Lupin Management Inc., USA		Novel Laboratories Inc. USA	-	,	Sale of goods or services		18.76	0.00				-						
301	Edpin Wanagement Inc., OSA		Nover Eaboratories Inc. OSA		Tellow Subsidiary	Expenses incurred on their behalf		10.70	0.00	0.00			-						
362	Lupin Management Inc., USA		Novel Laboratories Inc. USA		Fellow Subsidiary	recovered		3.14	0.00	0.00									
	Lupin Management Inc., USA		Lupin Inc., USA		Fellow Subsidiary	Sale of goods or services		79.31	0.00	0.00									
					,	Expenses incurred on their behalf													
364	Lupin Management Inc., USA		Lupin Inc., USA		Fellow Subsidiary	recovered		9.07	0.00										
365	Lupin Management Inc., USA		Lupin Research Inc. USA		Fellow Subsidiary	Receivables		0.00	0.00										
366	Lupin Management Inc., USA		Novel Laboratories Inc. USA			Receivables		0.00	16.57	11.82									
	Lupin Management Inc., USA		Lupin Inc., USA	-		Receivables		0.00	5.14										
	Lupin Management Inc., USA		Lupin Pharmaceuticals Inc. USA	-		Payables		0.00	2.20										
	Lupin Management Inc., USA		Lupin Research Inc. USA	_		Payables		0.00	3.94				_						
	Lupin Management Inc., USA	<u> </u>	Lupin Inc., USA	1	Fellow Subsidiary	Payables		0.00	0.00	13.83									
	Southern Cross Pharma Pty Limited Australia		Generic Health Pty Limited, Australia		Fellow Subsidiary	Sale of goods or services		12.19	0.00	0.00									